Glaucoma

March 27, 2018

Hormonal therapy for Glaucoma: Melatonin (N-acetyl-5-methoxy tryptamine), a hormone that regulates sleep and wakefulness, increases Nmnat1 expression, increases NAD+ levels, improves neuronal dysfunction, and protects against glaucoma via down regulation of its target gene, 27/March/2018, 5.41 am

Introduction: What they say A study from the The Jackson Laboratory, Bar Harbor, ME 04609, USA; Department of Ophthalmology, Tufts University of Medicine, Boston, MA 02111, […]
March 26, 2018

Gaseous therapy for Glaucoma: Hydrogen sulfide, a gaseous neurotransmitter, increases Nmnat1 expression, increases NAD+ levels, improves neuronal dysfunction, and protects against glaucoma via down regulation of its target gene, 26/March/2018, 6.19 am

Introduction: What they say A study from the The Jackson Laboratory, Bar Harbor, ME 04609, USA; Department of Ophthalmology, Tufts University of Medicine, Boston, MA 02111, […]
March 10, 2018

Molecular therapy for Glaucoma: Melatonin (N-acetyl-5-methoxy tryptamine), a regulator of sleep and wakefulness, increases Nmnat1 expression, increases NAD+ levels, improves neuronal dysfunction, and protects against glaucoma via down regulation of its target gene, 10/March/2018, 6.15 am

Introduction: What they say A study from the The Jackson Laboratory, Bar Harbor, ME 04609, USA; Department of Ophthalmology, Tufts University of Medicine, Boston, MA 02111, […]
March 10, 2018

Molecular therapy for Glaucoma: Astaxanthin, isolated from Haematococcus pluvialis, arctic shrimp among others, increases Nmnat1 expression, increases NAD+ levels, improves neuronal dysfunction, and protects against glaucoma via down regulation of its target gene, 10/March/2018, 5.55 am

Introduction: What they say A study from the The Jackson Laboratory, Bar Harbor, ME 04609, USA; Department of Ophthalmology, Tufts University of Medicine, Boston, MA 02111, […]